Quest Diagnostics Announces HSR Clearance for the Acquisition of Celera

Quest Diagnostics Incorporated DGX today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired in connection with the $8 per share all cash tender offer by its wholly-owned subsidiary, Spark Acquisition Corporation, to purchase all outstanding shares of common stock of Celera Corporation CRA.